Free Daily List of Top Penny Stocks to Buy – Good Penny Stocks

YUCAIPA, Calif., June 4, 2010 (GLOBE NEWSWIRE) — Ingen Technologies, Inc. (Pink Sheets:IGNT – News) the leading global medical device manufacturer of intelligent oxygen nasal cannulas focused on the $4 billion respiratory market, today announced that its innovative SMART Nasal Cannula with Oxyview technology are addressing unmet needs with an expected $200 million in revenues over the next 5 years.

Ingen has recently noticed a nice spike in sales from respiratory equipment manufacturers who require Ingen's gas flow meter technology for their own medical equipment.

Since 2007 when Ingen first introduced Oxyview to the world of COPD patients, the acceptance of the product has been impressive. There is no other product like Oxyview that provides the additional information that patients and clinicians rely upon. With approximately 23 million patients in the U.S. — and an estimated 600 million patients worldwide — who suffer from chronic obstructive pulmonary disease (COPD), Ingen stands to capture $200M in revenues over the next 5 years. Since an average COPD patient uses two to three nasal cannulas each month to prevent bacteria build-up within the device, creating a growing recurring demand for the cannula is an additional benefit to Ingen's bottom line.

View Fact Sheet: http://www.ingen-tech.com/PDFb…..tSheet.pdf

Ingen's SMART Nasal Cannula is superior and very different than that of the conventional oxygen nasal cannulas on the market that now are commoditized products and mass produced overseas and offer patients very little peace-of-mind. As a result, it is not uncommon for home care providers to make frequent visits to oxygen patients concerned that oxygen is not flowing from the tank to the cannula, since there is no way to accurately verify it.

Ingen's one-of-a-kind, patented, high quality SMART Nasal Cannula solves this problem by confirming the flow of oxygen and proper equipment function at roughly the same cost as a traditional cannula. The result is lower costs for home care providers and greater peace-of-mind for in-home oxygen patients with respiratory diseases like COPD.

“Ingen's innovative oxygen cannulas are rapidly gaining traction due to their unique ability to lower costs for home care providers and provide peace-of-mind for oxygen patients,” said Ingen CEO Scott Sand. “We have already booked more than $160,000 in revenues during the fourth quarter with $300,000 more in OEM orders backlogged, in addition to $1.4M in government contracts — and we're just scratching the surface.”

http://www.ingen-tech.com/

http://www.smartnasalcannula.com/

http://www.ingenpulseoximeter.com/

About Ingen:

Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/n…..pkgid=2472

News out on this one again this morning. Awesome volume coming in on this one today. I expect to see alot more from the company this week and weeks to come. Were at a great entry point here. There is rumors of the company announcing contracts after the bell. Hope to see that one hit the wire soon. Heres the latest news…

Ingen Unveils the New SMART Nasal Cannula at Alpha-1

YUCAIPA, Calif., June 14, 2010 (GLOBE NEWSWIRE) — Ingen Technologies, Inc. (Pink Sheets:IGNT – News), a medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S. and $8 billion globally, unveiled their new SMART Nasal Cannula in Orlando-Florida last week at the Alpha-1 19th Annual National Education Conference.

The Alpha-1 Association is a member-based not-for-profit organization dedicated to identifying those affected by Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improve the quality of their lives through support, education, advocacy and to encourage participation in research. Alpha-1-Antitrypsin Deficiency (Alpha-1) is a genetic disorder that can cause liver and lung disease in children and adults.

“We were very pleased to be an exhibitor and sponsor at this year's conference for Alpha-1. There are hundreds of patient members of the Alpha-1 Association, and many of them attended the conference, along with clinicians and physicians from around the globe. Our new SMART Nasal Cannula was featured and well accepted by the attendees. It is our goal to pick up the pace in supporting the various associations that support patients who require home oxygen therapy and the use of our products,” stated Scott R. Sand, CEO and Chairman of the Board.